John Burke, MD
Blood Cancers & Blood Disorders
SCRI at the 2026 ASCO® Annual Meeting
Colleagues from across SCRI's network will share research insights with oncology leaders from around the globe.
-
Check out our Accepted Abstracts and Presentations
-
Learn about our Expansive Network
-
Read the Press Release
-
Meet our Research Leaders
-
Find us at our Booth #22035
-
Read our Recent News
Colleagues from across SCRI's network will share research insights with oncology leaders from around the globe.
155+
Accepted Abstracts & Presentations
85+
Authors and Coauthors Across SCRI
55+
Early Phase Studies Featured
75+
Sponsors Represented
30+
Research Sites Represented Through Selected Abstracts & Presentations
Noteworthy Presentations by SCRI Experts
If you are member of the media who is interested in speaking with an expert from SCRI, please contact Becca Gelman at Becca.Gelman@SCRI.com.
Experts from across SCRI’s network will discuss the latest research findings that cover a variety of topics including:
James Essell, MD
Remote Therapeutic Monitoring
Peter Forsberg, MD
Blood Cancers & Blood Disorders
Erika Hamilton, MD
Breast Cancer
Melissa Johnson, MD
Lung Cancer
Hans Lee, MD
Blood Cancers & Blood Disorders
Mabel Mardones, MD
Breast Cancer
Meredith McKean, MD, MPH
Melanoma & Skin Cancer
We hope to see you in person at the 2026 ASCO® Annual Meeting.
Join us for our “Meet the Expert” series at our Booth #22035, where colleagues and experts including physician leaders from across the SCRI network will be on site daily to answer your questions and share their knowledge. Check out the calendar!
Learn More About Accelero™
Our accelerated operations model, Accelero maximizes all parts of SCRI to accelerate drug development and optimize clinical trial delivery. Coordinated through our CRO, SCRI Development Innovations, Accelero enhances connectivity to SCRI research sites, which in turn maximizes site contributions, optimizes site activation timelines, and synchronizes end-to-end clinical research management. Learn more.
SCRI Network’s Reach
SCRI has conducted more than 900 first-in-human trials, with more than 3,500 patients participating in treatment trials each year.